Core Viewpoint - The company has received approval from the National Medical Products Administration for the registration of Ephedrine Hydrochloride Injection, marking a significant milestone as the first domestic company to obtain this approval under the new classification system [1] Group 1: Product Development - Ephedrine Hydrochloride Injection is developed by Eton Pharmaceuticals, Inc. and was approved by the FDA in June 2021 under the brand name Rezipres [1] - The product is indicated for the treatment of clinically significant hypotension occurring during anesthesia [1] Group 2: Market Impact - The projected sales revenue for Ephedrine Hydrochloride Injection in 2024 is approximately 109 million yuan, reflecting a year-on-year growth of 14.35% [1]